Global Glaucoma Treatment Drugs Market Forecast to 2020 - New Product Launches Expected to Boost Market
August 2016
150
About the Report
About the Report
Ken Research announced its latest publication on "Global Glaucoma Treatment Drugs Market Forecast to 2020 - New Product Launches Expected to Boost Market" provides a comprehensive analysis of the glaucoma treatment drugs market. The report includes the market share contributed by the sales of generic and patented drugs globally for treatment of glaucoma. Further, the market in the study is differentiated by various parameters such as drug classes which include prostaglandin analogues, alpha agonist, beta blockers, carbonic Anhydrase inhibitors, cholinergic, and combined medications. On the basis of formulation, glaucoma treatment drugs market is categorized into topical eye drops, semisolid dosage forms and pills. The market is also segmented by six geographical regions across the globe - North America, Europe, Asia Pacific, Middle East, Latin America, and Rest of the World.
Detailed snapshot on key regions of the market which includes North America, Europe, and Asia Pacific is included in the report to elucidate facts about the market in detail. The study also highlights the detailed information about major drug manufacturers in the global glaucoma treatment drugs market and their respective shares by revenue in 2015. Analysis on pipeline products, patented drugs available in the market, and difference between generic and patented drugs is provided in the report to assist new entrants in understanding the market before investing in the market. Various marketing analysis factors such as trends and developments and Porter's five forces analysis are also added in the study for clear understanding about the factors responsible for present scenario of the market. The future analysis of overall global glaucoma treatment drugs market has also been discussed along with recommendations from analyst view.
Global Glaucoma Treatment Drugs Market
Glaucoma being the second common cause of blindness globally has emerged as a worldwide problem. It was estimated that approximately ~ million people were affected with glaucoma worldwide in year 2013. The statistics clearly advocates the high demand for glaucoma treatment drugs across the globe. It has been estimated that glaucoma treatment drugs generated USD ~ million of revenue in 2010. However, the revenue declined at a high rate till 2013, owing to the expiry of major patented drugs including ~ and ~. Although as a result of increasing prevalence of glaucoma, the market experienced steady growth afterwards and the market was valued at USD ~ million in 2015. Aging population and rising awareness in the emerging economies owing to the efforts of the government and NGOs were the major reasons which assisted the market in its growth during this period.
Glaucoma Treatment Drugs Market Segmentation
On the basis of drug class, Prostaglandin analogues dominated the glaucoma treatment drugs market with revenue share of ~% in 2015 owing to its efficacy to treat glaucoma and presence of two high revenue generating patented drugs including Travatan Z and Lumigan. Additionally, high sales of off-patent drug Xalatan also help the segment in generating high revenue. Beta blockers with revenue share of ~% in 2015 followed prostaglandin analogues majorly due to high preference for these drugs in India and China.
By geographical regions, North America dominated the market with revenue share of ~% in 2015. High prevalence of glaucoma, high awareness among people and economic stability to undergo expensive treatment options are the major factors which have driven the glaucoma treatment drugs market in North America. Approximately ~ million people in the US were affected from glaucoma in 2015. Low cost of the drugs in Europe with strong reimbursement and high presence of patient pool in Asia Pacific regions helped these respective regions capture second and third position in the global glaucoma treatment drugs market. Europe captured ~% share, by revenue followed by Asia Pacific with revenue share of ~% in the global market in 2015.
Generic versus Branded Glaucoma Drugs
Glaucoma being a highly prevalent disease demands for effective and affordable treatment options. The launch of generic drugs in the market during the historical period, especially of ~ has resulted in decline in revenue share of patented drugs in the market from ~% in 2010 to % in 2015. Low cost of generic drugs is the major factor which has resulted in high adoption of generic drugs in the market. It has been observed that branded drugs cost approximately five times that of generic drugs. However, low efficacy of generic drugs restricts the ophthalmologists in prescribing generic drugs over patented drugs in economically stable countries. It has been noted that generic drugs show diverse bioequivalence with change in temperature. In addition to this bottle's material, shape, and size, delivery dose drop size, and different pH also impacts the efficacy of generic drug, resulting in more number of side effects and higher time frame treatment.
Competitive Scenario
Alcon dominated the glaucoma treatment drugs market in 2015 with revenue share of ~% owing to its wide range of products in its portfolio and high demand for its two patented drugs Simbrinza and Travatan Z. Allergan followed Alcon with revenue share of ~% in 2015. Wide distribution network in addition to patented product portfolio including Lumigan and Alphagen/Combigan assisted Allergan in gaining second position in the market. Pfizer Inc. and Akorn Inc. captured third and fourth position in the market respectively. High sales of off-patent drug Xalatan helped Pfizer in attaining respective position in the market.
Key Topics Covered in the Report:
- The market size of Global Glaucoma Treatment Drugs Market
- Market segmentation of Global Glaucoma Treatment Drugs Market on the basis of Drug Class, Formulations, and Geographical Analysis
- Snapshot on North America Glaucoma Treatment Drugs Market
- Snapshot on Europe Glaucoma Treatment Drugs Market
- Snapshot on Asia Pacific Glaucoma Treatment Drugs Market
- Porter's Five Forces Analysis for Global Glaucoma Treatment Drugs Market
- Trends and Developments in Global Glaucoma Treatment Drugs Market
- Snapshot on Patented Glaucoma Treatment Drugs Market
- Generic Versus Branded Glaucoma Drugs
- Pipeline Analysis of Global Glaucoma Treatment Drugs Market
- Competitive Landscape and Detailed Company Profiles of the Major Market Players
- Future Outlook and Projections of Global Glaucoma Treatment Drugs Market
- Analyst Recommendations
- Macro-Economic Factors Impacting the Global Glaucoma Treatment Drugs Market
Products
Products
Lumigan, Travatan Z, Combigan, Xalatan, Simbrinza Suspension, Azopt, Zioptan, Istalol, Cosopt PF, Vasneo, Rhopressa, Roclatan, Trabodenoson, Prostaglandin Analogues, Beta Blockers, Alpha Agonists, Carbonic Anhydrase Inhibitors, Cholinergic, and Combination Medications
Companies
Alcon, Allergan plc, Akorn Inc., Bausch & Lomb Incorporated, Pfizer Inc, Merck & Co. Inc, Aerie Pharmaceuticals, Inotek Pharmaceuticals, Santen Pharmaceutical Co. Ltd
Table of Contents
Table of Contents
1. Executive Summary
Market Potential
Market Segmentation
Competitive Landscape
Generic versus Branded Glaucoma Drugs
Trends and Developments
Future Outlook and Projections
2. Research Methodology
2.1. Market Definitions
2.2. Abbreviations
2.3. Market Size and Modeling
Approach - Market Sizing
Market Sizing - Glaucoma Treatment Drugs Market
Limitations
3. Introduction
Types of Glaucoma
People at Risk
Symptoms of Glaucoma
Prevalence of Glaucoma
4. Global Glaucoma Treatment Drugs Market Size, 2010 - 2015
5. Global Glaucoma Treatment Drugs Market Segmentation
5.1. By Drug Class, 2015
5.2. By Formulations, 2015
5.3. By Geographical Regions, 2015
6. Snapshot on North America Glaucoma Treatment Drugs Market
6.1. United States
6.1.1. Prevalence of Glaucoma in the US
6.1.2. US Glaucoma Treatment Drugs Market
6.1.3. Patented Glaucoma Treatment Drugs Market in the US, 2015
6.1.4. US Glaucoma Treatment Drugs Market, by Drug Class
6.1.5. Regulatory Landscape
New Drug Approval Procedure
New Drug Timeline
Generic Drug Approval Procedure
Patents
Exclusivity
Glaucoma Drugs Reimbursement Scenario in the US
6.2. Canada
6.2.1. Prevalence of Glaucoma in Canada
6.2.2. Canada Glaucoma Treatment Drugs Market
6.2.3. Cost Comparison of Glaucoma Drugs in the US and Canada
6.2.4. Regulatory Landscape
Generic Drug Approval Procedure
Patents and Exclusivity
Pharmaceutical Pricing and Reimbursement in Canada
7. Snapshot on Europe Glaucoma Treatment Drugs Market
7.1. Prevalence of Glaucoma in Europe
7.2. Europe Glaucoma Treatment Drugs Market
7.3. Europe Glaucoma Treatment Drugs Market, by Drug Class
7.4. Europe Glaucoma Treatment Drugs Market, by Countries
7.5. Regulatory Landscape
7.5.1. New Drug Approval Procedure
7.5.2. Patents
7.5.3. Reimbursement Scenario in Europe
8. Snapshot on Asia Pacific Glaucoma Treatment Drugs Market
8.1. India
8.1.1. Prevalence of Glaucoma in India
8.1.2. India Glaucoma Treatment Drugs Market
8.1.3. India Glaucoma Treatment Drugs Market Segmentation by Drug Class, 2015
8.1.4. India Glaucoma Treatment Drugs Market, by Company
8.1.5. Regulatory Landscape
New Drug Approval Procedure
Patents
Pricing and Reimbursement Scenario in India
8.2. People's Republic of China (China)
8.2.1. Prevalence of Glaucoma in China
8.2.2. China Glaucoma Treatment Drugs Market
8.2.3. China Glaucoma Treatment Drugs Market Segmentation by Drug Class, 2015
8.2.4. Regulatory Landscape
New Drug Approval Procedure
Patents
8.3. Japan
8.3.1. Prevalence of Glaucoma in Japan
8.3.2. Japan Glaucoma Treatment Drugs Market
8.3.3. Regulatory Landscape
New Drug Approval Procedure
Patents
9. Global Glaucoma Treatment Drugs Market Competitive Landscape
9.1. Market Share of Glaucoma Drug Manufacturers in Global Glaucoma Treatment Drugs Market, 2015
9.2. Company Profiles for Key Manufacturers in Glaucoma Treatment Drugs Market
9.2.1. Allergan plc
9.2.2. Akorn, Inc.
9.2.3. Alcon
9.2.4. Bausch & Lomb Incorporated
9.2.5. Merck & Co. Inc.
9.2.6. Pfizer Inc.
10. Snapshot on Patented Glaucoma Treatment Drugs Market
11. Generic Versus Branded Glaucoma Drugs
12. Pipeline Analysis of Global Glaucoma Treatment Drugs Market
12.1. Phase III Drugs
12.2. Phase I and Phase II Drugs
12.3. Company Profiles
12.3.1. Aerie Pharmaceuticals
12.3.2. Inotek Pharmaceuticals
12.3.3. Santen Pharmaceutical Co. Ltd.
13. Trends and Developments in Global Glaucoma Treatment Drugs Market
13.1. Small Players Venturing into the Glaucoma Treatment Market
13.2. Acquisitions, Mergers, and Business Alliances
13.3. Unprecedented Medicare Cuts
13.4. Unawareness among Veteran Population
13.5. Rising Awareness Programs in Emerging Economies
13.6. Introduction of New Class of Drugs
14. Porter's Five Forces Analysis for Global Glaucoma Treatment Drugs Market
15. Future of Global Glaucoma Treatment Drugs Market
15.1. Future Outlook and Projections, 2016 - 2020
15.2. Cause and Effect Relationship between Dependent and Independent Factors Prevailing in Global Glaucoma Treatment Drugs Market
16. Analyst Recommendations
17. Macroeconomic Indicators
17.1. Aging Population
17.2. Number of People with Glaucoma
17.3. Glaucoma Surgical Devices Market
17.4. Emerging BRIC Economy
Disclaimer
Contact Us
List of Figure
Figure 4-1: Global Glaucoma Treatment Drugs Market on the basis of Revenue in USD Million, 2010 - 2015
Figure 6-1: US Glaucoma Prostaglandin Analogues Market by type of Prostaglandin Analogues on the basis of Revenue in Percentage, 2015
Figure 6-2: New Drug Approval Procedure in the US
Figure 6-3: New Drug Timeline in the US
Figure 6-4: ANDA Application Procedure for Generic Drug Approval in the US
Figure 6-5: Para IV Challenge against ANDA Paragraph IV Certification in the US
Figure 6-6: Patent Approval Procedure in the US
Figure 6-7: Drug Approval Procedure in Canada
Figure 7-1: Prevalence of Glaucoma in the European Countries in Percentage, 2015
Figure 7-2: Centralized Procedure for Drug Approval in Europe
Figure 7-3: Mutual Recognition Procedure for Drug Approval in Europe
Figure 7-4: Decentralized Procedure for Drug Approval in Europe
Figure 7-5: Patent Approval Procedure in Europe
Figure 8-1: Glaucoma Prevalence in India by Type of Glaucoma in Percentage, 2015
Figure 8-2: New Drug Approval Timeline in India
Figure 8-3: IND Application Procedure in India
Figure 8-4: NDA Approval Procedure in India
Figure 8-5: Patent Approval Procedure in India
Figure 8-6: Application for Approval of Clinical Study in China
Figure 8-7: Clinical Studies Procedure in China
Figure 8-8: Final Approval Procedure for Drug Registration in China
Figure 8-9: Patent Approval Procedure in China
Figure 8-10: IND Approval Process in Japan
Figure 8-11: Drug Approval Process in Japan
Figure 8-12: Timeline for Approval of New Drug in Japan
Figure 8-13: Patent Approval Procedure in Japan
Figure 9-1: Financial Performance of Allergan plc on the basis of Revenue in USD Million, 2013 - 2015
Figure 9-2: Financial Performance of Allergen plc by Operations on the basis of Revenue Contribution in Percentages, 2015
Figure 9-3: Financial Performance of Allergen plc by Operations on the basis of Revenue Contribution by Eye Care Therapeutic Area in terms of Percentages, 2015
Figure 9-4: Financial Performance of Allergan plc on the basis of Revenue Contributed by Glaucoma Treatment Drugs in USD Million, 2014 - 2015
Figure 9-5: Financial Performance of Akorn, Inc. on the basis of Revenue in USD Million, 2013 - 2015
Figure 9-6: Financial Performance of Akorn, Inc. on the basis of Revenue by Business Segments in USD Million, 2013 - 2015
Figure 9-7: Financial Performance of Akorn, Inc. on the basis of Revenue by US Sales and International Sales in USD Million, 2013 - 2015
Figure 9-8: Financial Performance of Alcon on the basis of Revenue in USD Million, 2013 - 2015
Figure 9-9: Financial Performance of Alcon by Business Segments on the basis of Revenue in terms of Percentages, 2015
Figure 9-10: Financial Performance of Alcon on the basis of Revenue Contributed by Glaucoma Treatment Drugs in USD Million, 2014 - 2015
Figure 9-11: Financial Performance of Bausch & Lomb Incorporated on the basis of Revenue (Estimated) in USD Billion, 2013 - 2015
Figure 9-12: Financial Performance of Bausch & Lomb Incorporated on the basis of Revenue Contributed by Glaucoma Treatment Drugs in USD Billion, 2014 - 2015
Figure 9-13: Financial Performance of Merck & Co. Inc. on the basis of Revenue in USD Million, 2013 - 2015
Figure 9-14: Financial Performance of Merck & Co. Inc. by Geographical Areas on the basis of Revenue in USD Million, 2013 - 2015
Figure 9-15: Financial Performance of Merck & Co. Inc. by Business Segments on the basis of Revenue in USD Million, 2013 - 2015
Figure 9-16: Financial Performance of Pfizer Inc. on the basis of Revenue in USD Million, 2013 - 2015
Figure 9-17: Financial Performance of Pfizer Inc. on the basis of Revenue Contributed by Glaucoma Treatment Drugs in USD Million, 2014 - 2015
Figure 9-18: Financial Performance of Pfizer by Geographical Regions on the basis of Revenue in Percentages, 2015
Figure 12-1: Financial Performance of Santen Pharmaceutical Co. Ltd. on the basis of Revenue in USD Million, 2013 - 2015
Figure 12-2: Financial Performance of Santen Pharmaceutical Co. Ltd. by Pharmaceutical Business Division Components on the basis of Revenue in Percentage, 2015
Figure 12-3: Financial Performance of Santen Pharmaceutical Co. Ltd. by Prescription Pharmaceutical Business Divisions Components on the basis of Revenue in Percentage, 2015
Figure 12-4: Financial Performance of Santen Pharmaceutical Co. Ltd. by Geographies on the basis of Revenue in Percentage, 2015
Figure 12-5: Financial Performance of Santen Pharmaceutical Co. Ltd. on the basis of Revenue generated by Glaucoma Prescription Drugs in USD Million, 2013 - 2015
Figure 14-1: Porters Five Forces Analysis for Global Glaucoma Treatment Drugs Market
Figure 15-1: Global Glaucoma Treatment Drugs Market Outlook and Future Projections on the Basis of Revenue in USD Million, 2016 - 2020
Figure 15-2: Comparative Analysis of Global Glaucoma Treatment Market by Drug Class on the basis of Revenue in Percentage in 2015 and 2020.
Figure 17-1: Global Aging Population in Millions, 2010 - 2020
Figure 17-2: Number of People with Glaucoma Globally in Millions, 2010 - 2020
Figure 17-3: Global Glaucoma Surgical Devices Market on the basis of Revenue in USD Billion, 2010 - 2020
Figure 17-4: Emerging BRIC Economies on the basis of GDP in USD Million, 2010 - 2020
List of Table
Table 4-1: Global Glaucoma Treatment Drugs Market and Rationale for Revenue, 2010 - 2015
Table 5-1: Global Glaucoma Treatment Drugs Market by Drug Class (Prostaglandin Analogs, Alpha Agonist, Beta Blockers, Carbonic Anhydrase Inhibitors, Cholinergic, and Combined Medications) and Rationale for Revenue, 2015
Table 5-2: Global Glaucoma Treatment Drug Classes, Major Branded Drugs and Generic Name
Table 5-3: Global Glaucoma Treatment Drugs Market by Drug Class (Prostaglandin Analogs, Alpha Agonist, Beta Blockers, Carbonic Anhydrase Inhibitors, Cholinergic, and Combined Medications) on the basis of Revenue, 2015
Table 5-4: Global Glaucoma Treatment Drugs Market by Formulations (Topical Eye Drops, Semisolid Dosage Forms, and Pills) and Rationale for Revenue, 2015
Table 5-5: Major Branded Drugs and Formulations
Table 5-6: Global Glaucoma Treatment Drugs Market by Formulations (Topical Eye Drops, Semisolid Dosage Forms, and Pills) on the basis of Revenue, 2015
Table 5-7: Global Glaucoma Treatment Drugs Market by Geographical Regions (North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the World) and Rationale for Revenue, FY'2011 - FY'2016
Table 5-8: Global Glaucoma Treatment Drugs Market by Geographical Regions (North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the World) on the basis of Revenue, 2015
Table 6-1: Prevalence of Glaucoma in the US, 2015
Table 6-2: US Glaucoma Treatment Drugs Market Key Point Indicators, 2015
Table 6-3: US Patented Drugs Glaucoma Market by Drugs (Combigan, Lumigan, Travatan Z, Simbrinza, Zioptan, Istalol, and Cosopt PF) on the Basis of Revenue, 2015
Table 6-4: US Patented Drugs Glaucoma Market by Major Players (Allergan, Alcon, Akorn Inc., and Bausch & Lomb Incorporated) on the Basis of Revenue, 2015
Table 6-5: US Glaucoma Treatment Drugs Market by Drug Class (Prostaglandin Analogues, Alpha Agonist, Combination Medications, Carbonic Anhydrase Inhibitors, Beta Blockers, and Cholinergic) on the Basis of Revenue, 2015
Table 6-6: Drug Approval Applications, Rationale, and Fees in the US, 2016
Table 6-7: Types of Drug Exclusivity, Rationale, and Time Period of Exclusivity
Table 6-8: Prevalence of Glaucoma in Canada, 2015
Table 6-9: Canada Glaucoma Treatment Drugs Market Key Point Indicators, 2015
Table 6-10: Key Glaucoma Treatment Drugs Available in Canada, Companies and Price in USD
Table 6-11: Cost Comparison of Glaucoma Drugs in the US and Canada in terms of USD
Table 6-12: Patent and Exclusivity Procedure in Canada and Rationale
Table 6-13: Patented Drugs in Canada Glaucoma Treatment Drug Market, Company, Patent Approval Date, and Patent Expiry
Table 7-1: Prevalence of Glaucoma in Europe
Table 7-2: Europe Glaucoma Treatment Drugs Market Key Point Indicators, 2015
Table 7-3: Key Glaucoma Treatment Drugs Available in Europe, Companies and Price in USD
Table 7-4: Europe Glaucoma Treatment Drugs Market by Drug Class (Prostaglandin Analogues, Beta Blockers, Combination Medications, Carbonic Anhydrase Inhibitors, Cholinergic, and Alpha Agonist) on the Basis of Revenue, 2015
Table 7-5: Europe Glaucoma Treatment Drugs Market Segmentation by Countries (Germany, France, Italy, Spain, and United Kingdom) on the basis of Revenue, 2015
Table 7-6: Product Price Regulation in Europe by Countries, 2016
Table 7-7: Control of Expenditure in Europe by Countries, 2016
Table 7-8: Industry Regulations in Europe by Countries, 2016
Table 7-9: Product Reimbursement in Europe by Countries, 2016
Table 8-1: Prevalence of Glaucoma in India, 2015
Table 8-2: India Glaucoma Treatment Drugs Market Key Point Indicators, 2015
Table 8-3: Key Glaucoma Treatment Drugs Available in India, Companies and Price in USD
Table 8-4: India Glaucoma Treatment Drugs Market by Drug Class (Prostaglandin Analogues, Beta Blockers, Alpha Agonists, Carbonic Anhydrase Inhibitors, Cholinergic, and Combination Medications) on the basis of Revenue, 2015
Table 8-5: India Glaucoma Treatment Drugs Market by Companies (Allergan, Alcon, Cipla, Cadila, and Others) on the basis of Revenue, 2015
Table 8-6: India Glaucoma Treatment Drugs Market Players and Rationale
Table 8-7: Prevalence of Glaucoma in China
Table 8-8: China Glaucoma Treatment Drugs Market Key Point Indicators, 2015
Table 8-9: Key Glaucoma Treatment Drugs Available in China, Companies and Price in USD
Table 8-10: China Glaucoma Treatment Drugs Market by Drug Class (Beta Blockers, Carbonic Anhydrase Inhibitors, Prostaglandin Analogues, Alpha Agonist, Combination Medications, and Cholinergic) on the basis of Revenue, 2015
Table 8-11: Prevalence of Glaucoma in Japan
Table 8-12: Japan Glaucoma Treatment Drugs Market Key Point Indicators, 2015
Table 8-13: Key Glaucoma Treatment Drugs Available in Japan, Companies and Price in USD
Table 9-1: Global Glaucoma Treatment Drugs Market by Manufacturers and Rationale for Revenue, 2015
Table 9-2: Global Glaucoma Treatment Drugs Market by Companies (Alcon, Akorn Inc., Allergan plc, Bausch & Lomb Incorporated, and Pfizer, Inc.) on the Basis of Revenue, 2015
Table 9-3: Company Profile of Allergan plc including Company Overview, Global Footprints, Product Portfolio, Eye Care Revenue, Business Strategies, Research and Development, Number of Employees, and Key Personnel
Table 9-4: Company Profile of Akorn, Inc. including Company Overview, Global Footprints, Product Portfolio, Business Strategies, Research and Development, Number of Employees, and Key Personnel
Table 9-5: Company Profile of Alcon including Company Overview, Global Footprints, Product Portfolio, Business Strategies, Financial Performance, Number of Employees, and Key Personnel
Table 9-6: Competitive Landscape of Bausch & Lomb Incorporated including Company Overview, Global Footprints, Product Portfolio, Business Strategies, Research and Development, Number of Employees, and Key Personnel
Table 9-7: Competitive Landscape of Merck & Co. Inc. including Company Overview, Global Footprints, Product Portfolio, Business Strategies, Research and Development, Number of Employees, and Key Personnel
Table 9-8: Competitive Landscape of Pfizer Inc. including Company Overview, Global Footprints, Product Portfolio, Business Strategies, Financial Performance, Research and Development, Number of Employees, and Key Personnel
Table 10-1: Patented Glaucoma Treatment Drugs and their Company, Patent Approval Year, Patent Expiration Year and Average Price in USD
Table 10-2: Patented Glaucoma Treatment Drugs on the basis of Revenue in Percentage, 2010 - 2015
Table 10-3: Patented Glaucoma Treatment Drugs on the basis of Revenue in USD Million, 2010 - 2015
Table 11-1: Difference between Generic and Branded Patented Drug on the basis of Cost, Bioequivalence and Efficacy, and Adherence
Table 11-2: Average Cost of Glaucoma Treatment Drugs on the basis of Branded Drugs and Generic Drugs in terms of USD per Unit as of August 2016
Table 12-1: Pipeline Analysis of Global Glaucoma Treatment Drugs Market on the basis of Drugs under Clinical Trials Phase III (2016), Sponsor and their Expected Launch Year and Sales in terms of USD Million
Table 12-2: Pipeline Analysis of Global Glaucoma Treatment Drugs Market on the basis of Drugs under Clinical Trials Phase I and II (2016), and Sponsor
Table 12-3: Company Profile of Aerie Pharmaceuticals including Company Overview, Products under Pipeline, Business Strategies, Financial Performance, Research and Development, Number of Employees, and Key Personnel
Table 12-4: Aerie Pharmaceuticals Research and Development Expenses in USD Thousands
Table 12-5: Rhopressa Competitive Advantage
Table 12-6: Roclatan Competitive Advantage
Table 12-7: Company Profile of Inotek Pharmaceuticals including Company Overview, Products under Pipeline, Business Strategies, Financial Performance, Research and Development, Number of Employees, and Key Personnel
Table 12-8: Inotek Pharmaceuticals Research and Development Expenses in USD Thousands
Table 12-9: Company Profile of Santen Pharmaceutical Co. Ltd. including Company Overview, Products under Pipeline, Product Portfolio, Business Strategies, Financial Performance, Research and Development, Number of Employees, and Key Personnel
Table 13-1: Small Players Venturing into Glaucoma Treatment Market and Rationale
Table 13-2: Acquisitions, Mergers, and Business Alliances in Glaucoma Treatment Drugs Market and Rationale, 2013 - 2016
Table 13-3: Glaucoma Awareness Programs in Emerging Economies and Rationale
Table 14-1: Porter's Five Forces Analysis for Global Glaucoma Treatment Drugs Market
Table 15-1: Future Drivers for Global Glaucoma Treatment Drugs Market
Table 15-2: Comparative Analysis of Global Glaucoma Treatment Market by Drug Class on the basis of Revenue in USD Million in 2015 and 2020.
Table 15-3: Cause and Effect Relationship between Industry Factors and Expected Industry Prospects in Global Glaucoma Treatment Drugs Market
Table 16-1: Recommendations for Global Glaucoma Treatment Drugs Market
Table 17-1: Rationale for Global Aging Population, 2010 - 2020
Table 17-2: Rationale for Number of People with Glaucoma Globally, 2010 - 2020
Table 17-3: Rationale for Global Glaucoma Surgical Devices Market, 2010 - 2020
Table 17-4: Rationale for Emerging BRIC Economy, 2010 - 2020
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.